Based on results from the CAPITello-291 phase III study, co-led by VHIO’s Mafalda Oliveira, Senior Medical Oncologist at Vall d’Hebron…
Results of the phase III LITESPARK-005 clinical trial show that treatment with belzutifan versus everolimus significantly improves progression-free survival in…
Now published in Annals of Oncology (1), updated meta-analysis provides insights into the efficacy of adoptive cell therapy with tumor-infiltrating…
Results of a preclinical, proof-of-concept study led by VHIO’s Stem Cells and Cancer Group demonstrate for the first time the…
More than 150 participants attended the second edition of the PhD Day at the Vall d’Hebron Campus. A day marked…
Announced by the European Medicines Agency (EMA) last month, June 21, the highly selective and potent VEGFR inhibitor fruquintinib has…
Extracellular vesicles shed by prostate cancer cells to the bloodstream contain tumor-derived material that can be used as biomarkers of…
The Evaluation Commission of health research institutes of the Instituto de Salud Carlos III has unanimously renewed the accreditation of…
This resource offers recommendations for written, oral, and visual communication in Catalan and English, aimed at research center personnel and…
Recently presented at the 2024 ASCO Annual Meeting and published in parallel in The Lancet Oncology, results of the OPTIMIZE-1…
Reported today during a Proffered Paper session at the ESMO Gastrointestinal Cancers Annual Congress (ESMO GI) 2024*, first health-related quality…
On the occasion of International LGBTQIA+ Pride Day, on June 28th, VHIO shows its commitment to diversity and equality. The…
